Search

Your search keyword '"Fanaroff, Alexander C."' showing total 298 results
Start Over Author "Fanaroff, Alexander C." Publication Type Academic Journals
298 results on '"Fanaroff, Alexander C."'

2. Two randomized controlled trials of nudges to encourage referrals to centralized pharmacy services for evidence-based statin initiation in high-risk patients: Rationale and design of the SUPER LIPID program

Author

Fanaroff, Alexander C., Huang, Qian, Clark, Kayla, Norton, Laurie A., Kellum, Wendell E., Eichelberger, Dwight, Wood, John C., Bricker, Zachary, Wood, Andrea G. Dooley, Kemmer, Greta, Smith, Jennifer I., Adusumalli, Srinath, Putt, Mary, and Volpp, Kevin G.M.

Published
2024
Full Text
View/download PDF

10. Racial Differences in Presentation and Outcomes After Peripheral Arterial Interventions: Insights From the NCDR-PVI Registry

Author

Julien, Howard M., Wang, Yongfei, Curtis, Jeptha P., Johnston-Cox, Hillary, Eberly, Lauren A., Wang, Grace J., Nathan, Ashwin S., Fanaroff, Alexander C., Khatana, Sameed Ahmed M., Groeneveld, Peter W., Secemsky, Eric A., Eneanya, Nwamaka D., Vora, Amit N., Kobayashi, Taisei, Barbery, Carlos, Jr, Chery, Godefroy, Kohi, Maureen, Kirksey, Lee, Armstrong, Ehrin J., Jaff, Michael R., and Giri, Jay

Published
2023
Full Text
View/download PDF

13. Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study.

Author

Fanaroff, Alexander C, Kaltenbach, Lisa A, Peterson, Eric D, Hess, Connie N, Cohen, David J, Fonarow, Gregg C, and Wang, Tracy Y

Subjects
Humans, Angina Pectoris, Cardiovascular Agents, Platelet Aggregation Inhibitors, Treatment Outcome, Patient Discharge, Prevalence, Risk Factors, Longitudinal Studies, Time Factors, Aged, Middle Aged, Drug Utilization Review, United States, Female, Male, Drug Prescriptions, Purinergic P2Y Receptor Antagonists, Percutaneous Coronary Intervention, Practice Patterns, Physicians', Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction, angina pectoris, guideline adherence, myocardial infarction, patient reported outcome, percutaneous coronary intervention, Practice Patterns, Physicians', Physicians, Cardiorespiratory Medicine and Haematology
Abstract

BackgroundAngina has important implications for patients' quality of life and healthcare utilization. Angina management after acute myocardial infarction (MI) treated with percutaneous coronary intervention (PCI) is unknown.Methods and resultsTRANSLATE-ACS (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) was a longitudinal study of MI patients treated with percutaneous coronary intervention at 233 US hospitals from 2010 to 2012. Among patients with self-reported angina at 6 weeks post-MI, we described patterns of angina and antianginal medication use through 1 year postdischarge. Of 10 870 percutaneous coronary intervention-treated MI patients, 3190 (29.3%) reported angina symptoms at 6 weeks post-MI; of these, 658 (20.6%) had daily/weekly angina while 2532 (79.4%) had monthly angina. Among patients with 6-week angina, 2936 (92.0%) received β-blockers during the 1 year post-MI, yet only 743 (23.3%) were treated with other antianginal medications. At 1 year, 1056 patients (33.1%) with 6-week angina reported persistent angina symptoms. Of these, only 31.2% had been prescribed non-β-blocker antianginal medications at any time in the past year. Among patients undergoing revascularization during follow-up, only 25.9% were on ≥1 non-β-blocker anti-anginal medication at the time of the procedure.ConclusionsAngina is present in one third of percutaneous coronary intervention-treated MI patients as early as 6 weeks after discharge, and many of these patients have persistent angina at 1 year. Non-β-blocker antianginal medications are infrequently used in these patients, even among those with persistent angina and those undergoing revascularization.

Published
2017

14. Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial.

Author

Fanaroff, Alexander C., Patel, Mitesh S., Chokshi, Neel, Coratti, Samantha, Farraday, David, Norton, Laurie, Rareshide, Charles, Zhu, Jingsan, Klaiman, Tamar, Szymczak, Julia E., Russell, Louise B., Small, Dylan S., and Volpp, Kevin G.M.

Subjects
*MONETARY incentives, *PHYSICAL activity, *RANDOMIZED controlled trials, *CONTROL (Psychology), *MAJOR adverse cardiovascular events, *PEDOMETERS
Abstract

BACKGROUND: Physical activity is associated with a lower risk of major adverse cardiovascular events, but few individuals achieve guideline-recommended levels of physical activity. Strategies informed by behavioral economics increase physical activity, but their longer-term effectiveness is uncertain. We sought to determine the effect of behaviorally designed gamification, loss-framed financial incentives, or their combination on physical activity compared with attention control over 12-month intervention and 6-month postintervention follow-up periods. METHODS: Between May 2019 and January 2024, participants with clinical atherosclerotic cardiovascular disease or a 10-year risk of myocardial infarction, stroke, or cardiovascular death of ≥7.5% by the Pooled Cohort equation were enrolled in a pragmatic randomized clinical trial. Participants received a wearable device to track daily steps, established a baseline, selected a step goal increase, and were randomly assigned to control (n=151), behaviorally designed gamification (n=304), loss-framed financial incentives (n=302), or gamification+financial incentives (n=305). The primary outcome of the trial was the change in mean daily steps from baseline through the 12-month intervention period. RESULTS: A total of 1062 patients (mean±SD age, 67±8; 61% female; 31% non-White) were enrolled. Compared with control subjects, participants had significantly greater increases in mean daily steps from baseline during the 12-month intervention in the gamification arm (adjusted difference, 538.0 [95% CI, 186.2–889.9]; P =0.0027), financial incentives arm (adjusted difference, 491.8 [95% CI, 139.6–844.1]; P =0.0062), and gamification+financial incentives arm (adjusted difference, 868.0 [95% CI, 516.3–1219.7]; P <0.0001). During the 6-month follow-up, physical activity remained significantly greater in the gamification+financial incentives arm than in the control arm (adjusted difference, 576.2 [95% CI, 198.5–954]; P =0.0028), but it was not significantly greater in the gamification (adjusted difference, 459.8 [95% CI, 82.0–837.6]; P =0.0171) or financial incentives (adjusted difference, 327.9 [95% CI, −50.2 to 706]; P =0.09) arms after adjustment for multiple comparisons. CONCLUSIONS: Behaviorally designed gamification, loss-framed financial incentives, and the combination of both increased physical activity compared with control over a 12-month intervention period, with the largest effect in gamification+financial incentives. These interventions could be a useful component of strategies to reduce cardiovascular risk in high-risk patients. REGISTRATION: URL: https://clinicaltrials.gov; Unique Identifier: NCT03911141. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Association Between Diagnosis-to-Limb Revascularization Time and Clinical Outcomes in Outpatients With Chronic Limb-Threatening Ischemia: Insights From the CLIPPER Cohort.

Author

Fanaroff, Alexander C., Dayoub, Elias J., Lin Yang, Schultz, Kaitlyn, Ramadan, Omar I., Wang, Grace J., Damrauer, Scott M., Genovese, Elizabeth A., Secemsky, Eric A., Parikh, Sahil A., Nathan, Ashwin S., Kohi, Maureen P., Weinberg, Mitchell D., Jaff, Michael R., Groeneveld, Peter W., and Giri, Jay S.

Published
2024
Full Text
View/download PDF

25. Association Between Cardiac Catheterization Laboratory Pre-Activation and Reperfusion Timing Metrics and Outcomes in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Report From the ACTION Registry

Author

Shavadia, Jay S., Roe, Matthew T., Chen, Anita Y., Lucas, Joseph, Fanaroff, Alexander C., Kochar, Ajar, Fordyce, Christopher B., Jollis, James G., Tamis-Holland, Jacqueline, Henry, Timothy D., Bagai, Akshay, Kontos, Michael C., Granger, Christopher B., and Wang, Tracy Y.

Published
2018
Full Text
View/download PDF

26. Patient and Staff Perceptions of Universal Severe Acute Respiratory Syndrome Coronavirus 2 Screening Prior to Cardiac Catheterization and Electrophysiology Laboratory Procedures

Author

Pothineni, Naga Venkata K., Starkey, Samantha, Conn, Kristine, Evans, Christina, Shah, Ronak, Hyman, Matthew C., Frankel, David S., Halaby, Rim, Johnston-Cox, Hillary A., Kunkel, Katherine, Nathan, Ashwin S., Seigerman, Matthew E., Herrmann, Howard C., Giri, Jay, Marchlinski, Francis E., Santangeli, Pasquale, and Fanaroff, Alexander C.

Published
2020
Full Text
View/download PDF

30. Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice: Insights From the Cardiac Care Outcomes Assessment Program (COAP) in Washington State

Author

Nathan, Ashwin S., Raman, Swathi, Yang, Nancy, Painter, Ian, Khatana, Sameed Ahmed M., Dayoub, Elias J., Herrmann, Howard C., Yeh, Robert W., Groeneveld, Peter W., Doll, Jacob A., McCabe, James M., Hira, Ravi S., Giri, Jay, and Fanaroff, Alexander C.

Published
2020
Full Text
View/download PDF

35. Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials

Author

Fanaroff, Alexander C., Clare, Robert, Pieper, Karen S., Mahaffey, Kenneth W., Melloni, Chiara, Green, Jennifer B., Alexander, John H., Jones, W. Schuyler, Harrison, Robert W., Mehta, Rajendra H., Povsic, Thomas J., Moreira, Humberto G., Al-Khatib, Sana M., Roe, Matthew T., Kong, David F., Mathews, Robin, Tricoci, Pierluigi, Holman, Rury R., Wallentin, Lars, Held, Claes, Califf, Robert M., Alexander, Karen P., and Lopes, Renato D.

Published
2019
Full Text
View/download PDF

39. A Path Forward for Regenerative Medicine: Navigating Regulatory Challenges: Summary of Findings From the Cardiac Safety Research Consortium/Texas Heart Institute International Symposium on Cardiovascular Regenerative Medicine

Author

Fanaroff, Alexander C., Morrow, Valarie, Krucoff, Mitchell W., Seltzer, Jonathan H., Perin, Emerson C., Taylor, Doris A., Miller, Leslie W., Zeiher, Andreas M., Fernández-Avilés, Francisco, Losordo, Douglas W., Henry, Timothy D., and Povsic, Thomas J.

Published
2018
Full Text
View/download PDF

48. Characteristics of Clinical Trial Sites for Novel Transcatheter Mitral and Tricuspid Valvular Therapies.

Author

Nathan, Ashwin S., Reddy, Kriyana P., Yang, Lin, Eberly, Lauren A., Dayoub, Elias J., Khatana, Sameed A. M., Julien, Howard M., Desai, Nimesh D., Szeto, Wilson Y., Herrmann, Howard C., Kobayashi, Taisei J., Fiorilli, Paul, Batchelor, Wayne B., Mehran, Roxana, Alkhouli, Mohamad Adnan, Giri, Jay, Groeneveld, Peter W., and Fanaroff, Alexander C.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results